New Patient Journey for Primary Mitochondrial Myopathies Launched
IMP has worked with ERN EURO‑NMD and several leading patient organisations, including Mitocon, the Bulgarian Association for Neuromuscular Diseases, and […]
IMP has worked with ERN EURO‑NMD and several leading patient organisations, including Mitocon, the Bulgarian Association for Neuromuscular Diseases, and […]
UMDF, in collaboration with UCB, has launched a new resource designed specifically for people living with TK2d and those who
On May 9, 2026, International Mito Patients was represented at the Cognate Amino Acid for tRNA Synthetase Disorders Consortium meeting
This year UCB is collaborating with the global Mitochondrial disease community to collect works of art (painting, poetry, photography, sculpture,
Five years ago, a research project began that is now influencing anesthetic practice worldwide. It all started when Dr. Yaremy
First Patient Dosed in Phase 3 KHENERFIN Study of Sonlicromanol for m.3243A>G Primary Mitochondrial Disease Khondrion has announced a major
European Commission approves KYGEVVI® for TK2d IMP warmly welcomes the decision by the European Commission to approve KYGEVVI® (doxecitine and doxribtimine) as
Announcing IMP’s New Scientific and Medical Advisory Committee IMP is delighted to introduce our new Scientific and Medical Advisory Committee, a
New MELAS Consensus: A Critical Resource for Doctors and Patients Worldwide In November 2025, leading international experts gathered in Pisa,
MitMED – Building a European Centre of Excellence in Mitochondrial Medicine Mitochondria are central regulators of cellular life, integrating metabolism,